Purpose To evaluate the difference in the diagnostic efficacy of F-18-PSMA-1007 PET/CT and pelvic MRI in primary prostate cancer, as well as the correlation between the two methods and histopathological parameters and serum PSA levels. Methods A total of 41 patients with suspected prostate cancer who underwent F-18-PSMA-1007 PET/CT imaging in our department from 2018 to 2023 were retrospectively collected. All patients underwent F-18-PSMA-1007 PET/CT and MRI scans. The sensitivity, PPV and diagnostic accuracy of MRI and F-18-PSMA-1007 PET/CT in the diagnosis of prostate cancer were calculated after comparing the results of MRI and F-18-PSMA-1007 PET/CT with biopsy. The Spearman test was used to calculate the correlation between F-18-PSMA-1007 PET/CT, MRI parameters, histopathological indicators, and serum PSA levels. Results Compared with histopathological results, the sensitivity, PPV and diagnostic accuracy of F-18-PSMA-1007 PET/CT in the diagnosis of prostate cancer were 95.1%, 100.0% and 95.1%, respectively. The sensitivity, PPV and diagnostic accuracy of MRI in the diagnosis of prostate cancer were 82.9%, 100.0% and 82.9%, respectively. There was a mild to moderately positive correlation between Gleason (Gs) score, Ki-67 index, serum PSA level and F-18-PSMA-1007 PET/CT parameters (p < 0.05). There was a moderately negative correlation between the expression of AMACR (P504S) and F-18-PSMA-1007 PET/CT parameters (p < 0.05). The serum PSA level and the Gs score were moderately positively correlated with the MRI parameters (p < 0.05). There was no correlation between histopathological parameters and MRI parameters (p > 0.05). Conclusion Compared with MRI, F-18-PSMA-1007 PET/CT has higher sensitivity and diagnostic accuracy in the detection of malignant prostate tumors. In addition, the Ki-67 index and AMACR (P504S) expression were only correlated with F-18-PSMA-1007 PET/CT parameters. Gs score and serum PSA level were correlated with F-18-PSMA-1007 PET/CT and MRI parameters. F-18-PSMA-1007 PET/CT examination can provide certain reference values for the clinical diagnosis, evaluation, and treatment of malignant prostate tumors.
基金：
Sichuan Provincial Science and Technology Department Project (No.2022YFS0068);Sichuan Cancer Hospital Outstanding Youth Funding (YB 2023022);Sichuan Cancer Hospital outstanding youth Fund (YB.2021029).
第一作者机构：[1]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Sichuan Canc Ctr,Dept Nucl Med,Affiliated Canc Hos, Chengdu, Peoples R China[2]Guangan Dist Peoples Hosp, Guangan, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Ye Zhenyan,Kou Ying,Shen Jiaqi,et al.A comparative study of 18F-PSMA-1007 PET/CT and pelvic MRI in newly diagnosed prostate cancer[J].BMC MEDICAL IMAGING.2024,24(1):doi:10.1186/s12880-024-01376-4.
APA：
Ye, Zhenyan,Kou, Ying,Shen, Jiaqi,Dang, Jun,Tan, Xiaofei...&Cheng, Zhuzhong.(2024).A comparative study of 18F-PSMA-1007 PET/CT and pelvic MRI in newly diagnosed prostate cancer.BMC MEDICAL IMAGING,24,(1)
MLA：
Ye, Zhenyan,et al."A comparative study of 18F-PSMA-1007 PET/CT and pelvic MRI in newly diagnosed prostate cancer".BMC MEDICAL IMAGING 24..1(2024)
